Abstract:Major depressive disorder (MDD) is a worldwide concern owing to its negative impact on the quality of life. Gamma-aminobutyric acid (GABA), an essential neurotransmitter in the brain, is important for regulating the enteric nervous system and gut-brain dual communication (gut-brain axis), thus providing gastrointestinal GABA and GABA-related pathways with possible targets for MDD treatment. However, the use of GABA for this disease remains limited due to its poor pharmacokinetic properties, including the low permeability through the blood-brain barrier, and the rapid clearance from the gastrointestinal tract. Since poly(amino acid)s are advantageous for improving the beneficial bioactivities of conventional amino acids, poly(gamma-aminobutyric acid) (poly(GABA)) is a potential candidate for MDD therapy. Nevertheless, the non-water-soluble and non-dispersible characteristics of poly(GABA) render difficulty in administering its conventional forms in vitro/in vivo, thereby hindering its therapeutic applications. Therefore, this study proposes a new design for poly(GABA) in nanoparticle form, which is composed of the amphiphilic diblock copolymers of poly(GABA) and poly(ethylene glycol), providing a suitable formulation for medication applications. Herein, we report on a new orally deliverable poly(GABA)-based nanoparticles (NanoGABA) in aqueous media and their efficacy on mouse depression models. NanoGABA treatment efficiently attenuated depression-like symptoms as evidenced by behavioral tests (forced swimming tests and tail suspension tests) and stress biomarkers (corticosterone). These findings suggest that the newly designed poly(GABA)-based nanoparticles are a promising candidate for the treatment of depression. STATEMENT OF SIGNIFICANCE: This research is the first to report the preparation of poly(GABA)-based nanoparticles in aqueous conditions with beneficial physical properties to open the gate for medical and pharmaceutical applications of poly (GABA). It is also a pioneer in using poly(GABA)-based materials for major depressive disorder therapeutics in vivo. Oral administration of NanoGABA attenuates depressive-like symptoms by targeting the enteric nervous system possibly through modulation of the gut-brain axis pathways with negligible toxicity, suggesting that NanoGABA is a promising therapeutic agent for major depressive disorders.

Physicochemical Characterization and Pharmacokinetics of Agomelatine-Loaded PLGA Microspheres for Intramuscular Injection

Development of a Novel Amorphous Agomelatine Formulation With Improved Storage Stability and Enhanced Bioavailability

Long-term sustained release Poly(lactic-co-glycolic acid) microspheres of asenapine maleate with improved bioavailability for chronic neuropsychiatric diseases

Development of Andrographolide Loaded PLGA Microspheres: Optimization, Characterization and in Vitro–in Vivo Correlation

Formulation Optimization and in Vitro Characterization of Granisetronloaded Polylactic-co-glycolic Acid Microspheres Prepared by a Dropping-in-liquid Emulsification Technique.

Enhancement of ocular anti-glaucomic activity of agomelatine through fabrication of hyaluronic acid modified-elastosomes: formulation, statistical optimisation , in vitro characterisation, histopathological study, and in vivo assessment

Effect of mPEG-PLGA on Drug Crystallinity and Release of Long-Acting Injection Microspheres: In Vitro and In Vivo Perspectives

A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers

LC-MS/MS Method for the Determination of Agomelatine in Human Plasma and Its Application to a Pharmacokinetic Study.

Pharmacological actions and clinical efficacy of agomelatine

A Novel Preparation Method for Octreotide Acetate–Loaded PLGA Microspheres with a High Drug‐Loading Capacity and a Low Initial Burst Release, and Its Studies on Relations Between in Vitro and in Vivo Release

Effects of Formulation Factors on Encapsulation Efficiency and Release Behaviour in Vitro of Huperzine A-Plga Microspheres

Poly(lactic-co-glycolic acid) microspheres for the controlled release of huperzine A: in vitro and in vivo studies and the application in the treatment of the impaired memory of mice.

Preparation Andin Vivo Evaluation of Huperzine A-loaded PLGA Microspheres

Preparation, Characterization and in Vitro Evaluation of IVM Loaded Poly(lactic-Co-Glycolic Acid) (PLGA) Microspheres

Preparation and in Vivo Pharmacokinetics of Rhgh-Loaded PLGA Microspheres.

PLGA Microspheres Prepared Via Aqueous-aqueous Emulsification for Pulsed Drug Delivery

Evaluation Of The Highly Variable Agomelatine Pharmacokinetics In Chinese Healthy Subjects To Support Bioequivalence Study

Designing poly(gamma-aminobutyric acid)-based nanoparticles for the treatment of major depressive disorders

Novel Triptorelin Acetate-Loaded Microspheres Prepared by a Liquid/oil/oil Method with High Encapsulation Efficiency and Low Initial Burst Release

Poly(alpha,L-glutamic acid) Microspheres for Oral Insulin Delivery